Abdullahi Ahmad1,2, Aurelia Prom3, John Bradley4, Mamadou Ndiath3, Blessed Etoketim3, Mamadou Bah3, Jean-Pierre Van Geertruyden5, Chris Drakeley6, Teun Bousema7, Jane Achan3, Umberto D'Alessandro3. 1. Disease Control and Elimination Theme, Medical Research Council Unit The Gambia At London, School of Hygiene and Tropical Medicine, P.O Box 273, Banjul, The Gambia. aahmad@mrc.gm. 2. Global Health Institute, University of Antwerp, Gouverneur Kinsbergencentrum, Campus Drie Eiken, Doornstraat 331, 2610, Wilrijk, Belgium. aahmad@mrc.gm. 3. Disease Control and Elimination Theme, Medical Research Council Unit The Gambia At London, School of Hygiene and Tropical Medicine, P.O Box 273, Banjul, The Gambia. 4. MRC Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. 5. Global Health Institute, University of Antwerp, Gouverneur Kinsbergencentrum, Campus Drie Eiken, Doornstraat 331, 2610, Wilrijk, Belgium. 6. Department of Immunology and Infection, School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. 7. Department of Medical Microbiology, Radboud University Medical Center, Geert Grooteplein 28, Microbiology 268, 6500 HB, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Treatment of clinical Plasmodium falciparum malaria with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) is associated with increased post-treatment gametocyte carriage. The effect of seasonal malaria chemoprevention (SMC) with SP and AQ on gametocyte carriage was assessed in asymptomatic P. falciparum infected children. METHODS: The study was carried out in eastern Gambia. Asymptomatic P. falciparum malaria infected children aged 24-59 months old who were eligible to receive SMC (SMC group) and children 5-8 years that were not eligible to receive SMC (comparison group) were recruited. Gametocytaemia was determined by molecular methods before and after SMC administration. Gametocyte carriage between the groups was compared using the chi-squared test and within-person using conditional logistic regression. RESULTS: During the 2017 and 2018 malaria transmission seasons, 65 and 75 children were recruited in the SMC and comparison groups, respectively. Before SMC administration, gametocyte prevalence was 10.7% (7/65) in the SMC group and 13.3% (10/75) in the comparison group (p = 0.64). At day 13 (IQR 12, 13) after SMC administration, this was 9.4% (5/53) in children who received at least the first dose of SMC treatment and 12.7% (9/71) for those in the comparison group (p = 0.57). Similarly, there was no difference in prevalence of gametocytes between children that adhered to all 3-day doses of SMC treatment 15.6% (5/32) and those in the comparison group (p = 0.68). In the SMC group, within-group gametocyte carriage was similar before and after SMC administration in children that received at least the first dose of SMC treatment (OR 0.6, 95% CI 0.14-2.51; p = 0.48) and in those that adhered to all 3-day doses of SMC treatment (OR 1.0, 95% CI 0.20-4.95; p = 1.0). CONCLUSION: In this study with relative low gametocyte prevalence prior to SMC treatment, no evidence was observed that SMC treatment increased gametocyte carriage in asymptomatic P. falciparum malaria infected children.
BACKGROUND: Treatment of clinical Plasmodium falciparum malaria with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) is associated with increased post-treatment gametocyte carriage. The effect of seasonal malaria chemoprevention (SMC) with SP and AQ on gametocyte carriage was assessed in asymptomatic P. falciparum infected children. METHODS: The study was carried out in eastern Gambia. Asymptomatic P. falciparum malaria infected children aged 24-59 months old who were eligible to receive SMC (SMC group) and children 5-8 years that were not eligible to receive SMC (comparison group) were recruited. Gametocytaemia was determined by molecular methods before and after SMC administration. Gametocyte carriage between the groups was compared using the chi-squared test and within-person using conditional logistic regression. RESULTS: During the 2017 and 2018 malaria transmission seasons, 65 and 75 children were recruited in the SMC and comparison groups, respectively. Before SMC administration, gametocyte prevalence was 10.7% (7/65) in the SMC group and 13.3% (10/75) in the comparison group (p = 0.64). At day 13 (IQR 12, 13) after SMC administration, this was 9.4% (5/53) in children who received at least the first dose of SMC treatment and 12.7% (9/71) for those in the comparison group (p = 0.57). Similarly, there was no difference in prevalence of gametocytes between children that adhered to all 3-day doses of SMC treatment 15.6% (5/32) and those in the comparison group (p = 0.68). In the SMC group, within-group gametocyte carriage was similar before and after SMC administration in children that received at least the first dose of SMC treatment (OR 0.6, 95% CI 0.14-2.51; p = 0.48) and in those that adhered to all 3-day doses of SMC treatment (OR 1.0, 95% CI 0.20-4.95; p = 1.0). CONCLUSION: In this study with relative low gametocyte prevalence prior to SMC treatment, no evidence was observed that SMC treatment increased gametocyte carriage in asymptomatic P. falciparum malaria infected children.
Authors: Karen I Barnes; Francesca Little; Aaron Mabuza; Nicros Mngomezulu; John Govere; David Durrheim; Cally Roper; Bill Watkins; Nicholas J White Journal: J Infect Dis Date: 2008-06-01 Impact factor: 5.226
Authors: Davis Nwakanma; Amani Kheir; Mercy Sowa; Sam Dunyo; Musa Jawara; Margaret Pinder; Paul Milligan; David Walliker; Hamza A Babiker Journal: Int J Parasitol Date: 2007-07-18 Impact factor: 3.981
Authors: Kim A Lindblade; Laura Steinhardt; Aaron Samuels; S Patrick Kachur; Laurence Slutsker Journal: Expert Rev Anti Infect Ther Date: 2013-06 Impact factor: 5.091
Authors: Cielo J Pasay; Rebecca Rockett; Silvana Sekuloski; Paul Griffin; Louise Marquart; Christopher Peatey; Claire Y T Wang; Peter O'Rourke; Suzanne Elliott; Mark Baker; Jörg J Möhrle; James S McCarthy Journal: J Infect Dis Date: 2016-04-07 Impact factor: 5.226
Authors: J L NDiaye; B Cissé; E H Ba; J F Gomis; C T Ndour; J F Molez; F B Fall; C Sokhna; B Faye; E Kouevijdin; F K Niane; M Cairns; J F Trape; C Rogier; O Gaye; B M Greenwood; P J M Milligan Journal: PLoS One Date: 2016-10-20 Impact factor: 3.240
Authors: Badara Cissé; El Hadj Ba; Cheikh Sokhna; Jean Louis NDiaye; Jules F Gomis; Yankhoba Dial; Catherine Pitt; Mouhamed NDiaye; Matthew Cairns; Ernest Faye; Magatte NDiaye; Aminata Lo; Roger Tine; Sylvain Faye; Babacar Faye; Ousmane Sy; Lansana Konate; Ekoue Kouevijdin; Clare Flach; Ousmane Faye; Jean-Francois Trape; Colin Sutherland; Fatou Ba Fall; Pape M Thior; Oumar K Faye; Brian Greenwood; Oumar Gaye; Paul Milligan Journal: PLoS Med Date: 2016-11-22 Impact factor: 11.069
Authors: Manon Alkema; Isaie J Reuling; Gerdie M de Jong; Kjerstin Lanke; Luc E Coffeng; Geert-Jan van Gemert; Marga van de Vegte-Bolmer; Quirijn de Mast; Reinout van Crevel; Karen Ivinson; Christian F Ockenhouse; James S McCarthy; Robert Sauerwein; Katharine A Collins; Teun Bousema Journal: J Infect Dis Date: 2021-10-13 Impact factor: 5.226